WilmerHale Advises Tetraphase Pharmaceuticals in Merger with AcelRx Pharmaceuticals 

WilmerHale Advises Tetraphase Pharmaceuticals in Merger with AcelRx Pharmaceuticals 

Client News

Related Solutions

Lawyers with deep and broad experience counseling clients in every industry on the design, implementation, and interpretation of executive compensation arrangements and on general compensation and benefits issues.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
WilmerHale lawyers have decades of experience advising public and private companies in all aspects of mergers and acquisitions.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
On March 16, 2020, Tetraphase Pharmaceuticals, Inc. (Nasdaq: TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA to treat serious and life-threatening infections, and AcelRx Pharmaceuticals (Nasdaq: ACRX) announced that they have entered into a definitive merger agreement pursuant to which AcelRx would acquire Tetraphase in a stock for stock transaction. Concurrently with signing the merger agreement, Tetraphase and AcelRx also entered into a co-promotion agreement to market and promote XERAVA™ for the treatment of complicated intra-abdominal infections and DSUVIA® for the treatment of acute pain in medically supervised settings.

WilmerHale is representing Tetraphase in the deal, with a team led by partners Stuart Falber, Hal Leibowitz and Chris Barnstable-Brown, which also included senior associate Tim Kulis and associate Meghan Fay on corporate and M&A matters, and partners Kim Wethly, Julie Hogan Rodgers, Scott Kilgore and Steve Barrett and associate Ben Kelsey on tax, executive compensation, employment and benefits and intellectual property matters. Associate Gerard Fischetti also worked on corporate and M&A matters. 

Read the full press release.
 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel